MPM BioVentures 2014, L.P. - Nov 30, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
Stock symbol
ITOS
Transactions as of
Nov 30, 2021
Transactions value $
-$2,878,562
Form type
4
Date filed
12/2/2021, 05:53 PM
Previous filing
Nov 30, 2021
Next filing
Dec 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale -$203K -5.86K -0.19% $34.62 3.01M Nov 30, 2021 See Footnote F1, F2, F3, F4
transaction ITOS Common Stock Sale -$988K -28.1K -0.93% $35.19 2.98M Nov 30, 2021 See Footnote F1, F5, F6, F7
transaction ITOS Common Stock Sale -$204K -6.04K -0.2% $33.82 2.98M Dec 1, 2021 See Footnote F1, F8, F9, F10
transaction ITOS Common Stock Sale -$189K -5.46K -0.18% $34.61 2.97M Dec 1, 2021 See Footnote F1, F11, F12, F13
transaction ITOS Common Stock Sale -$31.7K -896 -0.03% $35.34 2.97M Dec 1, 2021 See Footnote F1, F14, F15, F16
transaction ITOS Common Stock Sale -$1M -29.8K -1% $33.74 2.94M Dec 2, 2021 See Footnote F1, F17, F18, F19
transaction ITOS Common Stock Sale -$259K -7.43K -0.25% $34.83 2.94M Dec 2, 2021 See Fpotnote F1, F20, F21, F22
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
F2 The shares were sold as follows: 3,494 by MPM BioVentures 2014, L.P. ("BV 2014"), 120 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 2,206 by MPM BioVentures 2018, L.P. ("BV 2018") and 41 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.93 to $34.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The shares are held as follows: 1,707,933 by BV 2014, 97,289 by, 58,786 by AM BV2014, 1,078,695 by BV 2018, 48,966 by BV 2018(B) and 21,290 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F5 The shares were sold as follows: 16,733 by BV 2014, 576 by AM BV2014, 10,569 by BV 2018 and 198 by AM BV2018.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.93 to $35.465 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The shares are held as follows: 1,691,200 by BV 2014, 97,289 by BV 2014(B), 58,210 by AM BV2014, 1,068,126 by BV 2018, 48,966 by BV 2018(B) and 21,092 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F8 The shares were sold as follows: 3,600 by BV 2014, 124 by AM BV2014, 2,274 by BV 2018 and 44 by AM BV2018.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $34.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The shares are held as follows: 1,687,600 by BV 2014, 97,289 by BV 2014(B), 58,086 by AM BV2014, 1,065,852 by BV 2018, 48,966 by BV 2018(B) and 21,048 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F11 The shares were sold as follows: 3,251 by BV 2014, 112 by AM BV2014, 2,053 by BV 2018 and 41 by AM BV2018.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F13 The shares are held as follows: 1,684,349 by BV 2014, 97,289 by BV 2014(B), 57,974 by AM BV2014, 1,063,799 by BV 2018, 48,966 by BV 2018(B) and 21,007 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F14 The shares were sold as follows: 534 by BV 2014, 18 by AM BV2014, 337 by BV 2018 and 7 by AM BV2018.
F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F16 The shares are held as follows: 1,683,815 by BV 2014, 97,289 by BV 2014(B), 57,956 by AM BV2014, 1,063,462 by BV 2018, 48,966 by BV 2018(B) and 21,000 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F17 The shares were sold as follows: 17,728 by BV 2014, 611 by AM BV2014, 11,197 by BV 2018 and 221 by AM BV2018.
F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F19 The shares are held as follows: 1,666,087 by BV 2014, 97,289 by BV 2014(B), 57,345 by AM BV2014, 1,052,265 by BV 2018, 48,966 by BV 2018(B) and 20,779 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F20 The shares were sold as follows: 4,427 by BV 2014, 152 by AM BV2014, 2,796 by BV 2018 and 55 by AM BV2018.
F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F22 The shares are held as follows: 1,661,660 by BV 2014, 97,289 by BV 2014(B), 57,193 by AM BV2014, 1,049,469 by BV 2018, 48,966 by BV 2018(B) and 20,724 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.